Show notes
Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:Introduction (0:00)Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)CME information and select publications